SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Total revenue for the quarter ended March 2024 of  Rs. 119.73 millions remain, more or less, the same.The Net Loss for the quarter ended March 2024 is Rs. -58.48 millions as compared to Net Loss of Rs. -69.39 millions of corresponding quarter ended March 2023 Operating profit Margin for the quarter ended March 2024 improved to -29.04% as compared to -44.31% of corresponding quarter ended March 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 119.73 114.61 4.47 504.22 521.34 -3.28 504.22 521.34 -3.28
Other Income 2.10 1.93 8.81 4.51 6.20 -27.26 4.51 6.20 -27.26
PBIDT -29.04 -44.31 -34.46 -82.72 -151.59 -45.43 -82.72 -151.59 -45.43
Interest 12.72 10.28 23.74 46.89 29.73 57.72 46.89 29.73 57.72
PBDT -41.76 -54.59 -23.50 -129.61 -181.32 -28.52 -129.61 -181.32 -28.52
Depreciation 16.72 14.80 12.97 67.66 65.59 3.16 67.66 65.59 3.16
PBT -58.48 -69.39 -15.72 -197.27 -246.91 -20.10 -197.27 -246.91 -20.10
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -58.48 -69.39 -15.72 -197.27 -246.91 -20.10 -197.27 -246.91 -20.10
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -24.25 -38.66 -37.26 -16.41 -29.08 -43.58 -16.41 -29.08 -43.58

Krebs Biochem.&Inds Share Price

62.07 3.10 (5.26%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×